文献速递临床试验与 GCP

信迪利单抗联合化疗治疗不可切除胃癌或胃食管结合部癌:ORIENT-16随机临床试验

Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer: The ORIENT-16 Randomized Clinical Trial.
PubMed 文献 · JAMA · 2023-01-01

这项在中国62家医院开展的随机、双盲、安慰剂对照3期试验纳入650例不可切除局部晚期或转移性胃或胃食管结合部腺癌患者,比较信迪利单抗联合化疗与安慰剂联合化疗。信迪利单抗显著改善全部患者总生存(中位15.2个月 vs 12.3个月;分层HR 0.77,95%CI 0.63-0.94;P=0.009),PD-L1 CPS≥5患者中亦改善(中位18.4个月 vs 12.9个月;HR 0.66,95%CI 0.50-0.86;P=0.002)。

要点

  • 信迪利单抗联合化疗较安慰剂联合化疗显著改善全部患者总生存。
  • PD-L1 CPS≥5患者中信迪利单抗联合化疗同样显著改善总生存。
  • 最常见≥3级治疗相关不良事件为血小板计数降低、中性粒细胞计数降低和贫血。

核心结论

  • 在接受一线化疗的不可切除局部晚期或转移性胃或胃食管结合部腺癌患者中,信迪利单抗较安慰剂显著改善全部患者及PD-L1 CPS≥5患者的总生存。

研究设计与样本

  • 随机、双盲、安慰剂对照3期临床试验,在中国62家医院开展。
  • 2019年1月3日至2020年8月5日入组650例不可切除局部晚期或转移性胃或胃食管结合部腺癌患者,末次随访日期为2021年6月20日。
  • 患者按1:1随机分配至信迪利单抗组(n=327)或安慰剂组(n=323),联合卡培他滨和奥沙利铂(XELOX方案),每3周一次,最多6个周期;信迪利单抗或安慰剂联合卡培他滨维持治疗最长2年。
  • 主要终点为随机化后的总生存时间。

主要发现

  • 650例患者平均年龄59岁,男性483例(74.3%)。
  • 397例(61.1%)患者肿瘤PD-L1 CPS≥5。
  • 全部随机患者中信迪利单抗组较安慰剂组改善总生存:中位15.2个月 vs 12.3个月;分层HR 0.77(95%CI 0.63-0.94);P=0.009。
  • PD-L1 CPS≥5患者中信迪利单抗组较安慰剂组改善总生存:中位18.4个月 vs 12.9个月;HR 0.66(95%CI 0.50-0.86);P=0.002。
  • 最常见的≥3级治疗相关不良事件:血小板计数降低(信迪利单抗组24.7% vs 安慰剂组21.3%)、中性粒细胞计数降低(信迪利单抗组20.1% vs 安慰剂组18.8%)、贫血(信迪利单抗组12.5% vs 安慰剂组8.8%)。

关键数值与推荐

  • PD-L1 CPS评分范围为1-100,CPS≥5为预设亚组。
  • 全部随机患者总生存:信迪利单抗组中位15.2个月 vs 安慰剂组12.3个月;分层HR 0.77(95%CI 0.63-0.94);P=0.009。
  • PD-L1 CPS≥5患者总生存:信迪利单抗组中位18.4个月 vs 安慰剂组12.9个月;HR 0.66(95%CI 0.50-0.86);P=0.002。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 563例(86.6%)停止研究治疗,388例(59.7%)死亡,1例(<0.1%)失访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Gastric and gastroesophageal junction cancers are diagnosed in more than 1 million people worldwide annually, and few effective treatments are available. Sintilimab, a recombinant human IgG4 monoclonal antibody that binds to programmed cell death 1 (PD-1), in combination with chemotherapy, has demonstrated promising efficacy. OBJECTIVE: To compare overall survival of patients with unresectable locally advanced or metastatic gastric or gastroesophageal junction cancers who were treated with sintilimab with chemotherapy vs placebo with chemotherapy. Also compared were a subset of patients with a PD ligand 1 (PD-L1) combined positive score (CPS) of 5 or more (range, 1-100). DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind, placebo-controlled, phase 3 clinical trial conducted at 62 hospitals in China that enrolled 650 patients with unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma between January 3, 2019, and August 5, 2020. Final follow-up occurred on June 20, 2021. INTERVENTIONS: Patients were randomized 1:1 to either sintilimab (n = 327) or placebo (n = 323) combined with capecitabine and oxaliplatin (the XELOX regimen) every 3 weeks for a maximum of 6 cycles. Maintenance therapy with sintilimab or placebo plus capecitabine continued for up to 2 years. MAIN OUTCOMES AND MEASURES: The primary end point was overall survival time from randomization. RESULTS: Of the 650 patients (mean age, 59 years; 483 [74.3%] men), 327 were randomized to sintilimab plus chemotherapy and 323 to placebo plus chemotherapy. Among the randomized patients, 397 (61.1%) had tumors with a PD-L1 CPS of 5 or more; 563 (86.6%) discontinued study treatment and 388 (59.7%) died; 1 patient (<0.1%) was lost to follow-up. Among all randomized patients, sintilimab improved overall survival compared with placebo (median, 15.2 vs 12.3 months; stratified hazard ratio [HR], 0.77 [95% CI, 0.63-0.94]; P = .009). Among patients with a CPS of 5 or more, sintilimab improved overall survival compared with placebo (median, 18.4 vs 12.9 months; HR, 0.66 [95% CI, 0.50-0.86]; P = .002). The most common grade 3 or higher treatment-related adverse events were decreased platelet count (sintilimab, 24.7% vs placebo, 21.3%), decreased neutrophil count (sintilimab, 20.1% vs placebo, 18.8%), and anemia (sintilimab, 12.5% vs placebo, 8.8%). CONCLUSIONS AND RELEVANCE: Among patients with unresectable locally advanced or metastatic gastric and gastroesophageal junction adenocarcinoma treated with first-line chemotherapy, sintilimab significantly improved overall survival for all patients and for patients with a CPS of 5 or more compared with placebo. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03745170.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Xu J, Jiang H, Pan Y, et al. Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer: The ORIENT-16 Randomized Clinical Trial. JAMA. 2023. PMID: 38051328. doi:10.1001/jama.2023.19918

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。